Effects of Bacille Calmette-Guérin after the first demyelinating event in the CNS

Abstract

BCG, as compared to placebo, was associated with significantly reduced development of gadolinium-enhancing lesions in people with CIS for a 6-month period before starting immunomodulating therapy (Class I evidence).